Canadian Covid vaccine shows promise as Phase Three trials begin

Overall side effects were reported as mild and very short−lived

A Canadian COVID vaccine is showing promise.

The Medicago vaccine showed promising antibody results in hundreds of participants in a Phase 2 trial. The vaccine appears to produce 10 times the antibodies as are seen in people who have had COVID−19 with overall side effects reported as mild and very short−lived.

A Phase Three trial of the vaccine is underway. It’s the final step before Health Canada will consider it for use, which could happen this summer. Most Canadians are expected to have been vaccinated by then, so its most likely use will be as a booster shot. There have also been discussions about testing Medicago as a mix−and−match vaccine for second doses.

banner image via Pikist